
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

CROSSJECT Secures Additional BARDA Funding for the Development of the Zepizure
Details : The funding will be used for advancing the development of Zepizure (zeneo midazolam), an emergency treatment for the management of epileptic crisis.
Product Name : Zepizure
Product Type : Controlled Substance
Upfront Cash : Undisclosed
September 22, 2025

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hydrocortisone
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Eton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
CROSSJECT Updates on ZENEO Partnership with Eton for Adrenal Program
Details : ETON in-licensed commercialization rights to ZENEO® Hydrocortisone, a unique, and proprietary ready-to-use liquid formulation of hydrocortisone, for the US and Canadian markets.
Product Name : Zeneo
Product Type : Steroid
Upfront Cash : Undisclosed
March 25, 2025
Lead Product(s) : Hydrocortisone
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Eton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Midazolam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Bpifrance
Deal Size : $7.4 million
Deal Type : Financing
Crossject Wins €69M French Government Funding to Develop ZENEO® Epinephrine
Details : The proceeds will support development of crossject's ZENEO® Epinephrine needle-free autoinjector, for treatment of severe allergic reactions (anaphylactic shock).
Product Name : Zepizure
Product Type : Controlled Substance
Upfront Cash : Undisclosed
July 10, 2024
Lead Product(s) : Midazolam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Bpifrance
Deal Size : $7.4 million
Deal Type : Financing

Crossject announces highly successful closing of its €8 million rights offering
Details : The net proceeds will be used to support Crossject’s activities in bringing its Zepizure (midazolam), a short-acting hypnotic-sedative epileptic rescue therapy, to market.
Product Name : Zepizure
Product Type : Controlled Substance
Upfront Cash : Undisclosed
June 04, 2024

Crossject Signs a Geographic Extension of ZEPIZURE® Commercialization Agreement in Europe
Details : Under the terms of the agreement, Crossject Zepizure (midazolam) will be commercialized in the European market for the treatment of epileptic seizures.
Product Name : Zepizure
Product Type : Controlled Substance
Upfront Cash : Undisclosed
May 02, 2024

Crossject Obtains a Financing up To ‚¬12 Million, in Two Tranches
Details : The financing aims to support the clinical development of Zepizure (midazolam), a short-acting hypnotic-sedative medication currently undergoing evaluation in patients for epileptic seizures.
Product Name : Zepizure
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 27, 2024

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Midazolam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Syneos Health
Deal Size : Undisclosed
Deal Type : Agreement
Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®
Details : Under the agreement, Syneos Health will provide support in all pre-launch and launch activities for Zepizure (midazolam), an epileptic rescue therapy for epileptic seizures.
Product Name : Zepizure
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 04, 2024
Lead Product(s) : Midazolam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Syneos Health
Deal Size : Undisclosed
Deal Type : Agreement

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Midazolam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : $1.0 million
Deal Type : Agreement
Crossject signs ZEPIZURE® Commercialization Agreement for Northern Europe
Details : The agreement aims for the commercialization of Crossject's innovative rescue therapy for epileptic seizures Zepizure (midazolam), previously known as ZENEO® Midazolam, in northern Europe covering Germany, the UK, Denmark, Sweden, Finland and Norway.
Product Name : Zepizure
Product Type : Controlled Substance
Upfront Cash : Undisclosed
December 22, 2023
Lead Product(s) : Midazolam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : $1.0 million
Deal Type : Agreement

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zeneo
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zeneo is a Steroid drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
August 01, 2023
Lead Product(s) : Zeneo
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Midazolam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : AFT Pharmaceuticals
Deal Size : $0.7 million
Deal Type : Licensing Agreement
Details : Under the agreement, AFT will commercialise ZENEO® Midazolam, a combination of the single use needle-free auto injector ZENEO® and the drug product midazolam, in epileptic seizures in Australia and New Zealand.
Product Name : Zepizure
Product Type : Controlled Substance
Upfront Cash : Undisclosed
July 20, 2023
Lead Product(s) : Midazolam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : AFT Pharmaceuticals
Deal Size : $0.7 million
Deal Type : Licensing Agreement

 Reset All
Reset All